This blog post looks at the latest developments in European drug regulation, focusing on the new CBD regulations and their impact on Europe. The legalization of medical marijuana is gaining popularity around the world. With this in mind, it’s important to understand how different countries are approaching control of the cannabis plant and its derivatives. A growing number of nations are allowing CBD (Cannabidiol) oil, a non-psychoactive cannabinoid, in products meant to treat pain or other health issues. As a result, entrepreneurs who want to market CBD oil products must know where these laws stand in Europe.
This article will review CBD regulations in Europe and provide a brief introduction to the legal status of CBD in Europe.
History of CBD and the EMA (Europe Medicines Agency)
CBD first became popular in the 1990s when a group of scientists discovered that THC (Tetrahydrocannabinol) was an effective anti-cancer agent. When the team found that CBD (Cannabidiol) had similar anti-cancer properties, they decided to test the compound against tumours and found that CBD caused cancer cells to multiply. This discovery opened up the possibility of treating cancers with cannabis derivatives rather than traditional chemotherapy drugs. In 1999, a group of researchers from Israel performed a study on the effects of cannabis derivatives on mice. The study suggested that CBD could be a non-addictive alternative to anti-depressants and other psychiatric medications.
Besides its use as a therapeutic agent, researchers also began to look into CBD’s potential use in research for a range of other conditions. CBD was first made available to patients in Italy in 2001 when two Italian doctors petitioned the European Union to create a medical exemption to the Narcotics Act. This request was granted, and in 2002, CBD was legalized in Italy. CBD’s usage has since expanded to include various treatments for pain, epilepsy, and multiple sclerosis. After the EU passed the law, CBD has been available to patients in numerous forms, including oils, pills, and liquid sprays. The EU approved its first CBD drug in March 2012, after years of debate over how to regulate cannabinoids. At the time, the EMA stated that they would not approve the substance until it was tested on humans and found safe for use.
The team continued to test CBD’s effectiveness against many other diseases, including schizophrenia, epilepsy, neuropathy, Alzheimer’s, Parkinson’s and Huntington’s Disease. Following this research, the European Medicines Agency (EMA) authorized cannabidiol (CBD) to treat Dravet syndrome, a rare type of severe juvenile epilepsy that occurs in children.
EU Regulations on CBD
In June 2018, the European Parliament passed the ‘CBD Regulation’, which created a framework for European pharmaceutical companies to develop and market medical cannabis products. The CBD regulation is the first EU medical cannabis law to effect. In addition to CBD, other medical cannabis derivatives such as THC, CBN, CBC, and CBG have also been approved for use in various countries worldwide. This was good news for those suffering from chronic pain or other conditions that can benefit from CBD. Under this law, all medical cannabis products were under the same rules, making it easier for companies to apply for product approval in multiple countries across Europe. This CBD regulation requires that any companies selling CBD products be registered with the EMA. These companies will also need to prove that they have conducted extensive research into CBD’s effectiveness against certain diseases. A demonstration by the corporation that its products do not pose any harm to patients will be required before CBD can be lawfully marketed in Europe by the European Medicines Agency (EMA).
CBD Products in Europe
There are currently only a handful of CBD products on the market in Europe. Most of these products are sold in Italy, with CBD oil being the most popular form of CBD available. Many patients are turning to CBD for its potential anti-inflammatory properties, which can help ease their symptoms. The CBD products that have been approved in Europe are formulated to contain less than 2% THC. Other products contain higher amounts of THC, but these are not legal.
Medical Uses for CBD in Europe
Medical research into CBD continues to grow as scientists discover new ways to use the compound. CBD is now being explored for its potential to aid in treating a variety of illnesses, including Alzheimer’s disease, Parkinson’s disease, Dravet syndrome, epilepsy, multiple sclerosis, and others.
How Can I Sell CBD in Europe?
Indeed, it’s a great way to get involved in the booming CBD market. You can sell CBD in Europe as an affiliate marketer from your site, or you can sell CBD as an affiliate marketer on any of the thousands of affiliate networks available in Europe, like NewPhaseBlends. If you decide to sell CBD on one of these networks, we recommend using our recommended service, which gives you the best chance of making sales. Using our service, you can also sell CBD directly to customers in Europe, which is particularly convenient if you want to avoid the hassle of creating a separate website for each nation in which your business operates.
How Much Will It Cost To Sell CBD in Europe?
Selling CBD is easier than selling traditional medicines, and it doesn’t require any licensing, and there are no requirements that you have a physical presence in Europe. However, selling CBD online is much more competitive than it is for other medications because there are no barriers to entry. The competition is fierce, but it’s possible to make good money on CBD. For example, a person with a traffic-driving website can earn thousands of dollars a month by simply creating a page to sell CBD.
CBD is a fantastic natural remedy that has proven effective at treating a wide variety of conditions. By selling CBD products in Europe, you can generate a steady income for yourself while helping patients who need these products. If you’re interested in joining the growing market for CBD products, start selling CBD now. I’m a freelance writer, blogger, and author with over two decades of experience writing content for websites, business owners, and publications. In addition to my background in the Internet marketing industry, I also have a background in business and finance.